Therapeutic Efficacy of Intense Pulsed Light in the Treatment of Chalazion
1 other identifier
interventional
80
1 country
1
Brief Summary
Study method: This test screened the subjects first, and proposed to include 50 subjects with primary or recurrent eyelid plate gland cysts without obvious surgical indications. All subjects underwent three strong pulsed light therapy combined with eyelid plate gland massage, treatment of local anesthesia eye drops, and metal pads were placed in conjunctival sac protection. Eye protection, using the M22 strong pulsed light small optical treatment head of the medical company, energy selection 14-16J/cm2, laser position is selected on the upper and lower eyelids, 3mm away from the root of the eyelashes. Each interval is 3 weeks. Eye-related examinations were performed before treatment and 3 times after treatment. The evaluation content included: ocular surface, slit lamp observation, anterior segment photography, intraocular pressure, vision, corneal fluorescein staining, tear film rupture time, eyelid plate gland evaluation, eyelid plate gland cyst relief, eyelid plate gland cyst recurrence rate.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable
Started Aug 2021
Typical duration for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
August 23, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
October 30, 2021
CompletedFirst Submitted
Initial submission to the registry
August 21, 2022
CompletedFirst Posted
Study publicly available on registry
August 23, 2022
CompletedStudy Completion
Last participant's last visit for all outcomes
August 23, 2023
CompletedSeptember 21, 2022
September 1, 2021
2 months
August 21, 2022
September 17, 2022
Conditions
Outcome Measures
Primary Outcomes (1)
Recurrence rate of chalazia
The recurrence of the chalazia
An average of 1 year
Study Arms (2)
Experimental group
EXPERIMENTALReceiving IPL-MGD treatment.
Control group
ACTIVE COMPARATORAnother set of age, sex and diagnosis matched consecutive cases of chalazion, who received conservative treatment or excision with curettage but without IPL-MGX treatment as a control (Non-IPL group).
Interventions
conservative treatment or excision with curettage but without IPL-MGX treatment as a control
Eligibility Criteria
You may qualify if:
- Patients had primary or recurrent eyelid plate gland cyst without obvious surgical indications
You may not qualify if:
- (1) any intraocular inflammation, ocular infection, allergy, ocular surgery, or ocular trauma in the past 6 months; (2) any eyelid diseases or structural abnormality; (3) any systematic diseases may lead to dry eye or MGD; (4) skin cancer or pigmented lesion in the treatment zone.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Second Affiliated Hospital of Zhejiang University Hospital
Hangzhou, Zhejiang, China
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NON RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
August 21, 2022
First Posted
August 23, 2022
Study Start
August 23, 2021
Primary Completion
October 30, 2021
Study Completion
August 23, 2023
Last Updated
September 21, 2022
Record last verified: 2021-09